Wednesday, July 2, 2025 7/2/2025

COG NCTN Integrated Translational Science Center for Hematopoietic Malignancies in Children

Award Number: UG1CA233249
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 03/01/2022
PERIOD OF PERFORMANCE END DATE: 02/28/2026

Group Awards By:

View Award Description

COG NCTN Integrated Translational Science Center for Hematopoietic Malignancies in Children - Project Summary Hematopoietic malignancies including leukemias and lymphomas contribute to nearly half of all cancers and are a major cause of death from disease in children. The Children's Oncology Group (COG) has spearheaded efforts to improve outcome in children with cancer, and despite dramatic improvements in survival over the last several decades, relapse remains a major problem, and survivors may suffer long term complications from the cytotoxic therapy. Better understanding of the biology of malignancies allows for more rational, targeted approaches to therapy, minimizing the need or the intensity of the non-selective cytotoxic therapies. Such targeted approaches have transformed some diseases from uniformly fatal to highly curable ones (e.g., CML, APL), but a paucity of actionable targets has prevented broader application of targeted interventions in hematopietic malignancies. As part of its focus on optimizing the survival in pediatric cancers and improving quality of life for the cancer survivors, COG through partnerships with NCI has conducted a number of discovery phase studies to identify the biologic basis of cancer in children, with the goal of identifying specific targets for more appropriate risk stratification and directed therapies in its clinical trials. With the emerging data from pediatric (and adult) discovery phase studies, COG is poised to take the next step in identifying actionable targets for therapeutic intervention. As part of these efforts, COG has created the Network Group Integrated Translational Science Centers (ITSCs) aimed at providing resources for therapeutically driven translational research. COG Hematopoietic ITSC (HM-ITSC) has put into place intellectual (leadership) and physical resources (resource laboratories, biospecimens, etc.) to ensure rapid identification of actionable targets through carefully designed translational research projects, and fostering the experimental data through a carefully structured mechanism to clinical application. HM-ITSC is structured and integrated into the functional operations of the COG, with direct links to the COG Operations Office, Disease Committees, Network group Data and Statistics Center and Developmental Therapeutics in order to facilitate rapid flow of actionable translational biology data to clinical implementation within NCTN clinical trials. Hematopoietic Malignancies (HM) are a major cause of cancer in children and novel therapeutic targets are needed to optimizeoutcome. COG HM-Integrated Translational Science Center, integrated into the functional organization of COG, will provide resources to support translational research in pediatric leukemias and lymphomas towards identification of clinically meaningful targets and their incorporation into clinical trials.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $480,000 )
2025	2025	PUBLIC HEALTH INSTITUTE	555 12TH ST STE 600	OAKLAND	CA	94607	ALAMEDA	USA	Cancer Treatment Research	001	6	3/12/2025	SUPPLEMENT FOR EXPANSION	$480,000
2025	2025	PUBLIC HEALTH INSTITUTE	555 12TH ST STE 600	OAKLAND	CA	94607	ALAMEDA	USA	Cancer Treatment Research	002	6	3/31/2025	SUPPLEMENT FOR EXPANSION	$0
2025	2024	PUBLIC HEALTH INSTITUTE	555 12TH ST STE 600	OAKLAND	CA	94607	ALAMEDA	USA	Cancer Treatment Research	000	6	3/11/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $480,000

Issue Date FY: 2024 ( Subtotal = $427,843 )
2024	2024	PUBLIC HEALTH INSTITUTE	555 12TH ST STE 600	OAKLAND	CA	94607	ALAMEDA	USA	Cancer Treatment Research	002	6	5/14/2024	NON-COMPETING CONTINUATION	$0
2024	2024	PUBLIC HEALTH INSTITUTE	555 12TH ST STE 600	OAKLAND	CA	94607	ALAMEDA	USA	Cancer Treatment Research	001	6	4/18/2024	NON-COMPETING CONTINUATION	$39,999
2024	2024	PUBLIC HEALTH INSTITUTE	555 12TH ST STE 600	OAKLAND	CA	94607	ALAMEDA	USA	Cancer Treatment Research	000	6	3/13/2024	NON-COMPETING CONTINUATION	$387,844
														Subtotal = $427,843

Issue Date FY: 2023 ( Subtotal = $535,339 )
2023	2023	PUBLIC HEALTH INSTITUTE	555 12TH ST STE 600	OAKLAND	CA	94607	ALAMEDA	USA	Cancer Treatment Research	001	5	2/17/2023	NON-COMPETING CONTINUATION	$535,339
2023	2023	PUBLIC HEALTH INSTITUTE	555 12TH ST STE 600	OAKLAND	CA	94607	ALAMEDA	USA	Cancer Treatment Research	002	5	8/3/2023	NON-COMPETING CONTINUATION	$0
2023	2022	PUBLIC HEALTH INSTITUTE	555 12TH ST STE 600	OAKLAND	CA	94607	ALAMEDA	USA	Cancer Treatment Research	000	4	1/13/2023	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$0
														Subtotal = $535,339

Issue Date FY: 2022 ( Subtotal = $800,000 )
2022	2022	PUBLIC HEALTH INSTITUTE	555 12TH ST STE 600	OAKLAND	CA	94607	ALAMEDA	USA	Cancer Treatment Research	004	4	7/8/2022	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$901,096
2022	2022	PUBLIC HEALTH INSTITUTE	555 12TH ST STE 290	OAKLAND	CA	94607	ALAMEDA	USA	Cancer Treatment Research	001	4	4/1/2022	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$800,000
2022	2021	CHILDREN'S HOSPITAL OF PHILADELPHIA, THE	3401 CIVIC CENTER BLVD	PHILADELPHIA	PA	19104	PHILADELPHIA	USA	Cancer Treatment Research	000	3	3/31/2022	NON-COMPETING CONTINUATION	$0
2022	2021	CHILDREN'S HOSPITAL OF PHILADELPHIA, THE	3401 CIVIC CENTER BLVD	PHILADELPHIA	PA	19104	PHILADELPHIA	USA	Cancer Treatment Research	003	3	7/8/2022	NON-COMPETING CONTINUATION	-$800,000
2022	2020	CHILDREN'S HOSPITAL OF PHILADELPHIA, THE	3401 CIVIC CENTER BLVD	PHILADELPHIA	PA	19104	PHILADELPHIA	USA	Cancer Treatment Research	002	2	7/8/2022	NON-COMPETING CONTINUATION	-$101,096
														Subtotal = $800,000

Issue Date FY: 2021 ( Subtotal = $800,000 )
2021	2021	CHILDREN'S HOSPITAL OF PHILADELPHIA, THE	3401 CIVIC CENTER BLVD	PHILADELPHIA	PA	19104	PHILADELPHIA	USA	Cancer Treatment Research	001	3	3/1/2021	NON-COMPETING CONTINUATION	$800,000
2021	2020	CHILDREN'S HOSPITAL OF PHILADELPHIA, THE	3401 CIVIC CENTER BLVD	PHILADELPHIA	PA	19104	PHILADELPHIA	USA	Cancer Treatment Research	000	2	1/12/2021	NON-COMPETING CONTINUATION	$0
														Subtotal = $800,000

Issue Date FY: 2020 ( Subtotal = $800,000 )
2020	2020	CHILDREN'S HOSPITAL OF PHILADELPHIA, THE	3401 CIVIC CENTER BLVD	PHILADELPHIA	PA	19104	PHILADELPHIA	USA	Cancer Treatment Research	000	2	3/2/2020	NON-COMPETING CONTINUATION	$800,000
														Subtotal = $800,000

Issue Date FY: 2019 ( Subtotal = $800,000 )
2019	2019	CHILDREN'S HOSPITAL OF PHILADELPHIA, THE	3401 CIVIC CENTER BLVD	PHILADELPHIA	PA	19104	PHILADELPHIA	USA	Cancer Treatment Research	000	1	4/18/2019	NEW	$800,000
														Subtotal = $800,000

Grand Total All Awards = $4,643,182

Top

All Categories

About

Search

Reports

Data Submission

Award Information

COG NCTN Integrated Translational Science Center for Hematopoietic Malignancies in Children

Award Number: UG1CA233249

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 03/01/2022

PERIOD OF PERFORMANCE END DATE: 02/28/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer